46 results about "Vaccine manufacturing" patented technology

The invention discloses an A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process. The problem that highly-toxic chemical reagents, such as cyanogen bromide, are used in the vaccine manufacturing process in the prior art and accordingly are harmful to protection of human health and environment is solved. The A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process comprises the following steps of 1 cultivating Neisseria meningitidis, 2 utilizing the cultivated Neisseria meningitidis to extract crude polysaccharide, 3 purifying the crude polysaccharide to prepare refined Neisseria meningitidis polysaccharide and 4 activating and deriving the refined polysaccharide. The A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process has the advantages that the extraction rate of the polysaccharide from a capsule is higher, the precipitation rate of the polysaccharide is higher, the recovery rate and purity of the refined polysaccharide are high, the derivation effect is better and the like.

The invention discloses a recombination newcastle disease virus rLX/H9HA of H9 subtype avian influenza virus hemagglutinin albumen. A preservation number is CGMCCNo: 6652. According to the method, a reverse genetic operation platform of an established newcastle disease virus (DVA) weak poison LX strain is used, an HA gene of an H9N2 subtype avian influenza virus (AIV) epidemic strain A/Chicken/Jiangsu/WJ57/2012 is inserted in a genome overall length transcription carrier pLX of the LX strain, and thus a recombination newcastle disease virus genome overall length cDNA clone Plx-H9HA containing a H9N2 subtype AIVHA gene. A recombinant virus rLX/H9HA obtained through transfection on a chick embryo has high breeding geometric mean titer, can still express HA albumen stably through continuous passing of multiple generations, is suitable for mass production of vaccines, and can be used for vaccine manufacturing.

The invention relates to a DNA vaccine for preventing AIDS, the vaccine is the recombinant nucleotide of Gag, Pol and Env nucleotide sequence through the artificial modification of structural protein containing encoded Human Immunodificidncy Virus-1 (HIV-1), these vaccines are used as the transcript units for the biological synthesis of the virus protein antigen when applied in vivo. The beneficial effects of the invention include, (1) improved DNA vaccine manufacturing technique, (2) no integration indication detected, (3) the vaccine target antigen includes almost all the HIV-1 structural protein, such as GagPol and Env.

The invention relates to the technical field of vaccine anti-counterfeiting traceability, and discloses a preventive vaccine anti-counterfeiting traceability system based on the Internet of Things anda block chain, and the system comprises a local block database server A which is provided with vaccine traceability software in an installation and operation manner and is installed at a vaccine manufacturing place; and comprises first video acquisition equipment used for monitoring the whole process from raw materials to product manufacturing of vaccines; first vaccine detection and analysis equipment used for synchronously detecting basic preventive immune indexes of packaged vaccines in a product packaging process; date printing equipment used for printing a production date at the opening part of the sealing bag before the product packaging is about to be finished; wherein the block database of the vaccine traceability software stores video information of the whole process of manufacturing and packaging the sealed packaged vaccine printed with the specific production date and basic preventive immune index information. The vaccine anti-counterfeiting traceability system solves the technical problem that an existing vaccine anti-counterfeiting traceability system cannot fundamentally guarantee that vaccines inoculated by an inoculator belong to qualified products.

This disclosure provides universal influenza vaccines which can provide extended protection for several years, provide improved protection to circulating influenza strains that were not predicted accurately for annual vaccine manufacturing, and provide protection against newly emerging strains of influenza virus which carry the potential for establishing global pandemics.

The invention relates to a mink hemorrhagic pneumonia and botulism combined inactivate vaccine and a preparing method thereof.Strain WD005, strain DL007 and strain ZC118 of pseudomonas aeruginosa for vaccine manufacturing and detecting are obtained through clinical isolation, and the strains are higher in pertinence and more comprehensive in protection for current mink hemorrhagic pneumonia epidemic serotype; by means of virulence tests and immunogenicity tests, the immunogenicity is good; a strain C-type clostridium botulinum C62-4 has the advantage of being superior in immunogenicity.The combined inactivate vaccine can prevent attack of G-type pseudomonas aeruginosa, B-type pseudomonas aeruginosa, C-type pseudomonas aeruginosa and C-type clostridium botulinum to minks at the same time, and has the advantages that the number of inoculation times is reduced, and using is convenient.The labor intensity of immunization is relieved, the immune cost is reduced, the stress reaction of animals is reduced, and the vaccine is more economical and reliable.

The invention discloses a vaccine manufacturing process supervision method based on a block chain, belongs to the field of vaccine monitoring, and aims to solve the technical problem of how to supervise the vaccine manufacturing process. The method comprises the following steps: a block chain is deployed, and different users are taken as different nodes in the block chain; an intelligent contractis compiled, and the intelligent contract is deployed at each node; a production supplier node acquires product data information through the intelligent contract and stores the product data information into the block chain to generate a corresponding vaccine two-dimensional code or vaccine bar code; a detection department node scans the vaccine two-dimensional code or bar code to obtain product data information, and stores a transaction hash associated vaccine ID into an external database; a circulation structure node scans the vaccine two-dimensional code or bar code to obtain product data information, and the circulation data information and the vaccine ID are packaged and stored in the block chain through the intelligent contract; and a third-party department node scans the two-dimensional code or the bar code to obtain the product data information, the detection data information and the circulation data information.

The invention relates to the field of vaccine production, in particular to a packaging system for vaccine production and a using method of the packaging system. According to the packaging system for vaccine production and the using method of the packaging system, the risk that in the packaging process of vaccine production, a vaccine bottle opening with an aluminum package leaks again can be prevented. According to the technical scheme, the packaging system for vaccine production comprises two transverse moving frames, clamping plates, connecting rods and an arc frame, the bottom of each transverse moving frame is rotationally connected with one connecting rod, the middle of each connecting rod is fixedly connected with one clamping plate, and the clamping plates are fixedly connected with the arc frame; a plurality of arc frames are evenly arranged on the upper side and the lower side of the rear side of each clamping plate.

The invention belongs to the technical field of vaccine antigens, and discloses a method for preparing infectious bronchitis viral antigen by adopting non-immune eggs. The method comprises the following steps that infectious bronchitis non-immune eggs are adopted, pre-incubation conditions are controlled for pre-incubation; toxic strains of infectious bronchitis virus are inoculated on a chick embryo, and the inoculation dose is 105.0EID50/piece; after inoculation, post-incubation conditions are controlled for post-incubation, inspecting is still conducted after inoculation for 24 h, a dead embryo is discarded, after inoculation for 36 h, the chick embryo is placed into a cold storage chamber at 2-8 DEG C, and a virus allantoic fluid is obtained after 12 hours of cold storage; the virus titer of the obtained virus allantoic fluid is detected, and the virus allantoic fluid is concentrated and purified to obtain the infectious bronchitis viral antigen. According to the method, SPF eggs are replaced by the non-immune eggs, meanwhile the process conditions of the infectious bronchitis virus on the propagation of the non-immune eggs are determined, the quality of vaccine is ensured, thecost of vaccine research and production is also lowered, the huge reference value can be provided for vaccine manufacturing enterprises, and application prospects are broad.

The invention discloses stirring equipment for pneumonia vaccine production. The equipment comprises a base, a mounting shell is mounted on one side of the outer wall of the top of the base, a motor is mounted on the outer wall of one side of the mounting shell, an output shaft is mounted on the outer wall of one side of the output end of the motor, and a mounting frame is mounted on the outer wall of one side of the output shaft; and a first limiting circular groove is formed in the circumferential inner wall of the mounting shell, and first limiting rods are arranged on the inner walls of the top and the bottom of the first limiting circular groove correspondingly. According to the stirring equipment, through a rotating shaft and a driving gear arranged on a servo motor, a circular shafton a driven gear can be driven to rotate, spiral blades on the circular shaft mix raw materials in the stirring shell, the rotating directions of the spiral blades at the top and the bottom of the circular shaft are opposite, the raw materials can be moved to the middle, and the sufficient mixing is achieved; the accumulation of the raw materials is avoided, trapezoidal stirring plates on the outer wall of the circumference of the rotating shaft are used for mixing the raw materials again, so that the mixing efficiency is improved.

Methods and systems for generating a peptide sequence include transforming an input peptide sequence into disentangled representations, including a structural representation and an attribute representation, using an autoencoder model. One of the disentangled representations is modified. The disentangled representations, including the modified disentangled representation, are transformed to generate a new peptide sequence using the autoencoder model.

The invention discloses a method for preparing an influenza vaccine. The method comprises the following steps: preparing virus seeds; conducting micro-carrier suspension cultivation on Vero cells in a bioreactor; breeding a vaccine-made virus solution; inactivating and purifying the virus solution. The method adopts a cell line to replace a chicken embryo tissue for cultivation to prepare avian influenza viruses, and the problem that a chicken embryo itself has high possibility of being polluted by exogenous viruses can be solved; by the strict control on raw materials and the cultivation condition, the purity of prepared vaccine is guaranteed, and safety of the vaccine is ensured; the method adopts the bioreactor for vaccine preparation, is high in automation degree and simple and stable in preparation technology, and requires few operators required; the method can greatly reduce the preparation cost, is prevented from being restricted by raw material supply, and is short in preparation cycle; by adopting the method to prepare the vaccine, environmental pollution is less and is easy to handle; the conventional chick embryo preparation method can produce a great number of waste embryos and other waste, is great in handling difficulty, and relates to the problems of biological safety and public hygiene.

The invention discloses vaccine manufacturing equipment and a vaccine manufacturing process, and relates to the technical field of vaccine manufacturing devices.The vaccine manufacturing equipment comprises a stirring box, a stud is rotationally installed at the bottom of the stirring box, a vaccine stirring and mixing part is installed on the stud, and four supporting columns are fixedly installed at the bottom of the stirring box. The device is reasonable in structure, vaccine agents can be fully mixed and stirred and cannot be adhered to the stirring device, the agents deposited or adhered to the bottom of the stirring box can be scraped by a scraper, the agents can be fully mixed with the other agents, the quality of manufactured vaccines is better, water in the condensation pipe and the guide pipe circularly flows at the same time, and the efficiency is improved. Heat generated by stirring can be taken away, vaccines cannot be inactivated due to temperature rise, the stirring effect of the vaccine stirring device is better, medicaments cannot be polluted by the external environment, the vaccines are more stable in the manufacturing process, and the stirring device is easy to operate, convenient to clean, wide in application range and high in practicability.

The invention discloses a vaccination verification system, a vaccination verification method and a vaccination verification contract platform based on an intelligent contract, and the vaccination verification system, the vaccination verification method and the vaccination verification contract platform based on the intelligent contract can realize decentration of an application program. According to the technical scheme, high mutual trust among the first client serving as an inoculator, the second client serving as a medical care and the contract platform is achieved, participation of human factors is reduced, the phenomena of information leakage and masquerading are avoided, rapid popularization of vaccines is facilitated, and in addition, vaccine manufacturers can also carry out vaccine production planning according to registration information.

A composition for increasing vaccine yields due to increased virus growth in mutation comprising a vaccine strain bearing the Y161F mutation in hemagglutinin (HA). Y161F in HA increases HA thermostability without changing its original antigenic properties and enhances its binding affinity in the vaccine production platforms used in influenza vaccine manufacturing. A method for optimizing preparation of influenza vaccine seed strains which can further lower the cost of vaccines and increase profits for the vaccine companies, and also maintain antigenic stability during vaccine deliveries.

The invention relates to the technical field of vaccine production, in particular to an embryonated egg post hatching device for poultry vaccine production. The embryonated egg post hatching device for poultry vaccine production comprises a hatching tray, wherein a hatching assembly is fixedly arranged on the upper surface of the hatching tray; a support post is fixedly arranged on the upper surface of the hatching tray; a top plate is fixedly arranged on the top end of the support post; a rack is arranged on the upper surface of the top plate in a penetrating way; a hatching cover covering the hatching assembly is fixedly arranged at the bottom end of the rack; a first electric motor arranged in a way of corresponding to the rack is fixedly arranged on the lower surface of the top plate;a gear engaged with the rack is fixedly arranged on the tail end of an output shaft of the first motor; and a plurality of uniformly distributed support legs are fixedly arranged on the lower surfaceof the hatching tray. Through an embryonated egg detection module arranged in the hatching device, the detection can be performed without taking embryonated eggs out of the device; and meanwhile, allof the embryonated eggs can be detected by one industrial camera, so that the cost is lower.

The invention discloses a method for preparing a human encephalitis B inactivated vaccine and the vaccine, and belongs to the field of vaccine manufacturing, the method for preparing the human encephalitis B inactivated vaccine sequentially comprises the following steps: S1, serum-free adaptive domestication of Vero cells on a culture flask; s2, performing serum-free multiplication culture on the Vero cells on the bioreactor; s3, inoculating JEV on the Vero cells in the bioreactor; s4, harvesting, inactivating, concentrating and purifying viruses; s5, carrying out freeze-drying treatment on the vaccine stock solution; the Japanese encephalitis inactivated vaccine has the effects of improving the safety of the Japanese encephalitis inactivated vaccine for people and reducing the side effects of the Japanese encephalitis inactivated vaccine for people.